Opinion

Video

Real-World Data for Risdiplam in Adult Patients with Spinal Muscular Atrophy

Panelists examine the available real-world data (RWD) on the use of risdiplam in adult patients with spinal muscular atrophy (SMA) from various studies conducted worldwide, discussing its potential efficacy and safety as a treatment option for adult SMA patients.

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Related Videos
Anna Pace, MD
Kristyn Pocock, MD
Dementia expert James Galvin, MD, MPH, a professor of neurology at the University of Miami Miller School of Medicine, and chief scientific officer at CogniVue
Rami Burstein, PhD
Michael Kaplitt, MD, PhD
2 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.